tbuckley/cabot-search huggingface dataset:
Abstract 43: Role of Ets-1 in the regulation of energy metabolism in cancer cells
Authors: Meghan L. Verschoor, Chris P. Verschoor, Gurmit Singh
Journal: Cancer Research (2010)

Abstract Cancer cells predominantly utilize glycolysis for ATP production even in the presence of abundant oxygen, an environment that would normally result in energy production through oxidative phosphorylation. Although the molecular mechanism for this metabolic switch to aerobic glycolysis has not been fully elucidated, it is likely that mitochondrial damage to the electron transport chain and the resulting increased production of reactive oxygen species (ROS) are significant driving forces. In this study, we have investigated the role of the transcription factor Ets-1 in the regulation of mitochondrial function and metabolism. Microarray analysis of the effects of Ets-1 over-expression in 2008 ovarian cancer cells was conducted using the Affymetrix GeneChip® Human Gene 1.0ST Array. Our findings show that Ets-1 up-regulates key enzymes involved in glycolysis and associated feeder pathways, fatty acid metabolism, and antioxidant defense. Additionally, Ets-1 down-regulates genes involved in the citric acid cycle, electron transport chain, and mitochondrial proteins. These results were validated using real-time qRT-PCR. The mitochondrial activity of both ovarian cancer Ets-1 over-expressing and breast cancer Ets-1 down-regulating cells was evaluated by examining oxygen consumption using various electron transport chain inhibitors (Oxygraph 2k), growth in the absence of glucose, and sensitivity to the glycolytic inhibitor 2-DG. We have found that Ets-1 expression is directly correlated with cellular oxygen consumption whereby increased expression causes decreased oxygen consumption. Ets-1 over-expression also caused increased sensitivity to glycolytic inhibitors, as well as pronounced growth inhibition in a glucose-depleted culture environment. In the context of ROS production, Ets-1 up-regulation induces a significant reduction in H2O2 production, likely due to Ets-1-mediated up-regulation of antioxidants. Collectively, our findings show that Ets-1 is involved in the regulation of cellular metabolism and response to oxidative stress in cancer cells. (This work was supported by operating grants to GS provided by the Canadian Institutes of Health Research) Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2010;70(8 Suppl):Abstract nr 43.
SPECT and Planar Imaging of a Lingual Thyroid Gland
Authors: Michael E Spieth, Purushotham Veluvolu, Stacey L Schmitz
Journal: Clinical Nuclear Medicine (2003)

SPIETH, MICHAEL E. M.D.; VELUVOLU, PURUSHOTHAM M.D.; SCHMITZ, STACEY L. C.N.M.T. Author Information
1426 IMMUNOGENICITY AND SAFETY OF TWO DOSES OF INVESTIGATIONAL HEPLISAV™ COMPARED TO THREE DOSES OF LICENSED HEPATITIS B VACCINE (ENGERIX-B®) IN TWO PHASE 3 TRIALS
Authors: R. Janssen, S. Bennett, H. Namini, W. Heyward, J. Martin
Journal: Journal of Hepatology (2013)
Renal Hemorrhage Detection With Tc-99m Labeled Erythrocytes in a Patient With Polycystic Disease
Authors: FERNANDO CESANI, ERIC WALSER, ELMA G. BRISCOE, JAVIER VILLANUEVA-MEYER
Journal: Clinical Nuclear Medicine (1996)

A 47-year-old man with polycystic kidney disease, who was on hemodialysis for several years, presented with gross hematuria. Although radionuclide imaging is successfully used to detect minimal gastrointestinal bleeding with Tc-99m labeled RBCs, this technique is not usually applied to the evaluation of genitourinary bleeding because there is some excretion of free pertechnetate by the kidneys. The authors report the successful identification of a renal hemorrhage in a patient with polycystic kidneys using labeled RBC scintigraphy. This finding is important because it guided the surgeon to remove the appropriate kidney.
IMPACT OF CHRONIC KIDNEY DISEASE ON CLINICAL OUTCOMES IN PATIENTS WITH DIABETES MELLITUS UNDERWENT PERCUTANEOUS CORONARY INTERVENTION USING DRUG-ELUTING STENT
Authors: Young Jin Youn, Su-Min Kim, Ji Hyun Lee, Jun-Won Lee, Sung-Gyun Ahn, Sung-Gyun Ahn, Min-Soo Ahn, Jang-Young Kim, Byung-Su Yoo, Seung-Hwan Lee, Junghan Yoon
Journal: Journal of the American College of Cardiology (2015)
AB0866 Presence of Acrocyanosis in Patients with Joint Hypermobility
Authors: A. Dinc, G. Keskin
Journal: Annals of the Rheumatic Diseases (2014)

<h3>Background</h3> Joint hypermobility is a common but often poorly recognized connective tissue condition with joint laxity in the absence of any hereditary systemic disease. Acrocyanosis is symmetric, painless, blue discoloration in the distal parts of the body with aggravation by cold exposure, and frequent association with local hyperhidrosis of hands and feet. Primary acrocyanosis is mostly a disease of young adults, only few cases persist into middle age. <h3>Methods</h3> A group of 200 consecutive rheumatology patients (&lt;45 yrs. old) investigated for joint laxity and acrocyanosis. For each patient a Beighton score measured and those with a score of &gt;4 regarded as benign joint hypermobility due to Brighton criteria. Acrocyanosis was diagnosed clinically by proper history and physical examination. Other relevant clinical findings were also recorded. <h3>Results</h3> A total of 24 patients (F: M, 12:12) were diagnosed as hypermobility. Nearly all patients had a mild-moderate hypermobility. The mean Beighton score was 4.2±0.4. Of those patients, 11 had also acrocyanosis (%45.8). In the remaining group (176), only two cases of acrocyanosis detected (%0.01). In the group with acrocyanosis, hand and foot size proportionate to stature is larger than those without. <h3>Conclusions</h3> It has been known that, patients with hypermobility may have some vascular problems, including Raynaud9s phenomenon and varicose veins. Our observation points out that, besides joint hypermobility, vessel wall laxity might cause to passive engorgement of vascular structures, namely acrocyanosis. <h3>Disclosure of Interest</h3> None declared <h3>DOI</h3> 10.1136/annrheumdis-2014-eular.5595
Insulin Resistance — Mechanisms, Syndromes, and Implications
Authors: D E Moller, J S Flier
Journal: New England Journal of Medicine (1991)

The past 20 years have witnessed a remarkable increase in our knowledge of the cellular and molecular mechanisms that underlie the diverse actions of insulin, the central hormone of metabolic regulation. Interest in the molecular details of insulin action has been heightened by the prevalence of insulin resistance and by the fact that insulin resistance has a key role in the pathogenesis of many disorders, including obesity, diabetes mellitus, ovarian hyperan-drogenism, and possibly hypertension. In this review, we discuss current concepts of the mechanisms of insulin action and insulin resistance and the implications of insulin resistance for a variety of . . .
Abstract 5407: Tumor penetrating microparticles enhance siRNA delivery and expression in pancreatic cancer
Authors: Jie Wang, Ze Lu, Jing Gu, Mingjian Cui, Joy Dorsten, M. Guillaume Wientjes, Jessie L-S. Au
Journal: Cancer Research (2011)

Abstract A major challenge for using siRNA as cancer therapeutics is the delivery to solid tumors, due to their unfavorable physicochemical properties (negative charges, large molecular size, and instability). Our laboratory has developed paclitaxel-loaded tumor-penetrating microparticles (TPM) for intraperitoneal therapy of peritoneal tumors (JPET, 327: 673-682, 2008). Embedded in the design of TPM is the tumor priming technology to promote nanomedicine delivery in solid tumors (JPET, 322:80-88, 2007). The goal of this study was to evaluate whether TPM can improve siRNA delivery and expression for treating solid tumors located in the peritoneal cavity. Nanoparticles containing survivin siRNA (siRNA-NP) were developed. Survivin, a major resistance factor, is selectively expressed in tumors and upregulated by various chemotherapeutic agents. The activity of paclitaxel (agent loaded in TPM) and siRNA was investigated in cultured cells using the clonogenic assay and the survivin level determined using western blotting. In vivo activity was evaluated in peritoneal pancreatic HS766T xenograft tumors; the pharmacodynamic endpoints were reduction of proliferation index (measured by Ki67 labeling), induction of apoptosis (measured by caspase 3 expression), prolongation of survival time, and survivin protein level (measured by immunohistochemical staining and quantitative image analysis using NIH ImageJ). The two negative controls were blank nanoparticles (without siRNA) and non-targeting siRNA. In cultured cells, siRNA-NP produced protein knockdown, decreased cell clonogenicity, and enhanced paclitaxel activity. However, siRNA-NP did not produce protein knockdown or antitumor activity in tumors grown in animals, indicating insufficient delivery in vivo. In contrast, when given in combination with TPM, siRNA-NP produced survivin knockdown and enhanced the antitumor activity of TPM. The results indicate that TPM treatment improves the delivery and transfection of siRNA in intraperitoneal tumors in vivo and suggest potential therapeutic utility of coadministered TPM and siRNA-NP combination. Supported in part by research grants R44CA103133 and R43CA134047 from NCI, DHHS. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2011;71(8 Suppl):Abstract nr 5407. doi:10.1158/1538-7445.AM2011-5407
Abstract SY12-02: Epstein-Barr virus (EBV) and cancer: Opportunities for etiologic research and prevention
Authors: Allan Hildesheim
Journal: Cancer Research (2012)

Abstract Infections are known to cause approximately one in every five cancers. Helicobacter pylori (H. pylori), human papillomavirus (HPV), and hepatitis (B &amp; C) infections each account for approximately 5% of cancers each year. Understanding the role of these infections in cancer etiology has led to numerous promising approaches to primary and secondary prevention, including prophylactic vaccination (HPV &amp; HBV), screening (HPV), and treatment (H. pylori &amp; HCV). EBV is a ubiquitous infection that establishes lifelong latency. Infection with EBV has been shown to be linked to the development of a subset of various forms of lymphoma, nasopharyngeal carcinomas, salivary gland cancers, and gastric cancers, totaling approximately 200,000 new cases each year worldwide. In addition, in countries where first infection with EBV tends to occur in late childhood or early adulthood, EBV is responsible for infectious mononucleosis (150,000 cases per year in the US alone), a condition that is typically benign but associated with prolonged morbidity. Despite our knowledge that EBV is associated with the development of various cancers, little attention has been placed to date on potential measures to prevent diseases associated with this common infection. In this presentation, our understanding of the link between EBV infection and cancer is summarized, and the potential for applying our knowledge to cancer prevention efforts discussed. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr SY12-02. doi:1538-7445.AM2012-SY12-02
Late autologous transplantation in chronic myelogenous leukemia with peripheral blood progenitor cells mobilized by G-CSF and interferon-α
Authors: M Michallet, A Thiébaut, I Philip, C Charrin, C Vigouroux, X Thomas, K Bilger, A Belhabri, D Guyotat, B Corront, B Salles, C Dumontet, PY Péaud, JP Vilque, A Devidas, D Fière
Journal: Leukemia (2000)
SAT0467 Long Term Outcome and Foki VDR Polimorphism in JIA Patients on Anti-TNF Treatment
Authors: J. Vojinovic, T. Jeftovic, D. Lazaraevic, G. Susic
Journal: Annals of the Rheumatic Diseases (2013)

<h3>Background</h3> <b>C</b>ontribution of FoxI VDR (vitamin D receptor) polymorphism on disease outcome in JIA is not yet well established. <h3>Objectives</h3> To investigate influence of FoxI VDR polymorphism on long term outcome in JIA patients. <h3>Methods</h3> FokI VDR polymorphism was evaluated using the PCR-RFLP method in 82 JIA patients included in Serbian JIA registry treated with anti-TNF agent (etanercept) and 20 helthy controls. Observational period was 6 years. <h3>Results</h3> Disease subtype distribution was 6.78% systemic, 54.24% poly RF- and extended oligo, 18.64% poly RF+, 16.95% ERA and 3.38 PsA. During follow up period 47,8% of pts. could stop treatment after average of 33 months (12-60 months) and achieved remission which have lasted 13,72 (2-48) months at cut off point. At the time cut off point 52,2 % of the pts. were still under biologic treatment with average treatment duration 42 (12-79) months while 37,5% of them could not stop treatment at any time point and 62,5% achieved short time remission which lasted 12,71 (2-48) months. Extended oligo and ERA JIA subtype significantly correlated with need to continue biologic treatment. The distribution of VDR genotypes was not significantly different among JIA subtypes. VDR genotypes distribution was 51.6% FF, 38.7% Ff and 9.7% ff while in 20 healthy controls only FF (wild type) genotype was present. Presence of f genotype significantly correlated with worse outcome and disease severity. <h3>Conclusions</h3> Our results indicate that JIA patients, more frequently than healthy controls, have Ff or ff VDR FokI polymorphism. Presence of f variant for FokI polymorphism of VDR in JIA patients was associated with worse outcome and longer need for biologic treatment. <h3>Disclosure of Interest</h3> None Declared
Scintigraphic Evaluation of Malignant Melanoma Lesions With Tc-99m Tetrofosmin
Authors: Omar Alonso, Miguel Martinez, Fernando Mut, Jose Bruno, Lucia Delgado, Graciela Lago, Margarita Nuñez, Carlos Bazzano, Jose Espasandin, Eduardo Touya
Journal: Clinical Nuclear Medicine (1998)

Two cases of malignant melanoma (primary and metastatic lesions) imaged with Tc-99m tetrofosmin are reported. One patient showed intense uptake in a primary skin lesion of the thorax, and the other patient had accumulation in skin, cerebellum, breast, and lymph node metastases. Like Tc-99m MIBI, Tc-99m tetrofosmin imaging may be of clinical relevance in the evaluation of suspicious skin lesions and in patients with known cutaneous malignant melanoma in the assessment of recurrent disease during follow-up evaluation.
Peroral video cholangioscopy to evaluate indeterminate bile duct lesions and preoperative mucosal cancerous extension: a prospective multicenter study
Authors: M. Osanai, T. Itoi, Y. Igarashi, K. Tanaka, M. Kida, H. Maguchi, K. Yasuda, N. Okano, H. Imaizumi, F. Itokawa
Journal: Endoscopy (2013)

Despite the development of peroral video cholangioscopy (PVCS), no prospective multicenter studies have been undertaken to investigate the diagnostic accuracy of PVCS in biliary tract diseases. Therefore, the aim of this study was to clarify the accuracy of PVCS in evaluating biliary tract lesions.This study was a prospective multicenter study at five tertiary referral centers in Japan and included 87 eligible patients with biliary tract diseases who underwent PVCS. The study evaluated the ability of PVCS to diagnose indeterminate biliary tract diseases, detect mucosal cancerous extension preoperatively in extrahepatic bile duct cancers, and predict adverse events.The use of PVCS appearance alone correctly distinguished benign from malignant indeterminate biliary lesions in 92.1 % of patients whereas biopsy alone was accurate in 85.7 %. In extrahepatic bile duct cancer, mucosal cancer extended histologically at least 20 mm in 34.7 % (17/49) of patients. The accuracy rate of PVCS to evaluate the presence or absence of mucosal cancerous extension by endoscopic retrograde cholangiography (ERC) alone, ERC with PVCS, and ERC with PVCS + biopsy were 73.5 %, 83.7 %, and 92.9 %, respectively. Adverse events were seen in 6.9 % of PVCS patients, but no serious complications were observed.PVCS enhanced the accurate diagnosis of biliary tract lesions by providing excellent resolution in combination with biopsy.
Prognostic significance of human papillomavirus (HPV) tumor status for patients with head and neck squamous cell carcinoma (HNSCC) in a prospective, multi-center phase II clinical trial
Authors: C. Fakhry, W. Westra, S. Li, A. Cmelak, J. Ridge, H. Pinto, A. Forastiere, M. Gillison
Journal: Journal of Clinical Oncology (2007)

6000 Background: Retrospective, single-institution studies suggest that patients with HPV- positive (HPV+) HNSCC may have a better prognosis than patients with HPV-negative (HPV-) tumors. Methods: The effect of tumor HPV status on treatment response and survival outcomes was prospectively evaluated in a multi-center, phase II clinical trial conducted by the Eastern Cooperative Oncology Group. Patients with newly diagnosed, resectable, stage III or IV HNSCC of the oropharynx or larynx were uniformly treated with two cycles of induction chemotherapy (IC; paclitaxel 175 mg/m 2 and carboplatin AUC 6) followed by chemoradiation (CRT; weekly paclitaxel 30 mg/m 2 administered concurrently with standard fractionation external beam radiation therapy, total dose of 70 Gy in 35 fractions over 7 weeks). Tumor HPV status was determined by in situ hybridization on formalin-fixed, paraffin-embedded tumors. The independent effect of tumor HPV status on survival was evaluated by Cox-proportional hazards models. Results: Genomic DNA of oncogenic HPV type 16, 33, or 35 was specifically located within tumor cell nuclei of 40% (95%CI 29.7- 50.1) of evaluable cases. Factors associated with HPV+ tumor in univariate analysis included Caucasian race (p=0.02), improved ECOG performance status (p=0.01), an oropharyngeal primary (p&lt;0.001), early tumor stage (p=0.02), and basaloid histology (P&lt;0.001). Response rates assessed after IC (81.6% vs. 55.2%, p=0.01) and CRT (84.2% vs. 56.9%, p=0.07) were higher in patients with HPV+ than HPV- tumors. After a median follow-up time of 39.1 months, patients with HPV+ tumors had a risk of progression that was 72% lower (HR=0.28, 95% CI: 0.07–1.0) and a risk of death that was 79% lower (HR=0.21, 95% CI: 0.06–0.74) than patients with HPV- tumors, after adjustment. Conclusion: The improved prognosis of HPV+ HNSCC has been confirmed in a prospective clinical trial and may be explained in part by enhanced sensitivity to chemotherapy and radiation. No significant financial relationships to disclose.
FRI0130 Fatigue, feeling blue and obesity, but not disease activity, predict whether patients with early inflammatory arthritis are able to walk considerable distances
Authors: G. Westhoff, J. Callhoff, E. Edelmann, A. Zink
Journal: Annals of the Rheumatic Diseases (2013)

<h3>Background</h3> Whether or not patients with inflammatory arthritis (IA) are still walking a considerable distance does not only depend on disease activity but also on many other chronic conditions that are frequently prevalent in middle aged individuals. <h3>Objectives</h3> To assess the association between patients' characteristics at the beginning of rheumatologic care and the ability to walk 3 km one year thereafter. <h3>Methods</h3> 603 patients participating in an observational study on early arthritis (&lt;6 months; CAPEA 2010-2013) were followed with respect to the self-reported ability to walk 3 km after 12 months of rheumatologic care (with no or minor trouble vs. with great trouble or not at all). In a multivariate logistic regression analysis we included sex, education (compulsory, secondary, higher), smoking (never, past, currently), body mass index (BMI &lt;25, 25-30, &gt;30), 12 common chronic conditions (yes/no), RF and/or ACPA serology (negative, low-positive, high-positive), as well as the baseline arthritis parameters acute phase reactants (CRP and ESR normal vs. CRP or ESR abnormal), tender and swollen joint counts (T/SJC28 0-3, 4-10, &gt;10), self-reported pain, morning stiffness and fatigue (VAS 0-3, 4-6, 7-10), and the first item of the Patient Health Questionnaire Depression scale (PHQ9):"Having little pleasure or interest in doing things" (not at all, on several days, more than half of the days). <h3>Results</h3> Patients (66% female) were 56 ±14 years old and had symptom duration of 13 ±7 weeks. 59% were RF and/or ACPA positive, 66% fulfilled the new ACR-EULAR RA criteria at baseline and 88% took DMARDs at 12 months. At this point in time, 31% of the patients reported that they could not walk the distance of 3 km at all or only with great trouble. In multivariate logistic regression analysis, none of the arthritis activity measures or any of the considered cardiovascular, metabolic, pulmonary or degenerative diseases were associated with that outcome. Instead, failing to walk 3 km without considerable trouble was significantly associated with age, severe fatigue, feeling blue frequently, and obesity (Table). Overall, 66% of the patients reported at least one of the three critical conditions. <h3>Conclusions</h3> Whether or not patients with early arthritis are managing a 3 km walking distance without considerable trouble depends on health conditions that are usually not in the focus of routine rheumatologic care. Since two thirds of the IA patients had at least one of the conditions potentially hampering walking around, these conditions should be focussed in routine rheumatologic care. <h3>Disclosure of Interest</h3> None Declared